Sign In
Buy TBPH
$16.86
+0.0100 (+0.0593%)
At Close: Jul 31, 2026
Theravance Biopharma, Inc. (TBPH) Q1 2025 Earnings Call Transcript
04:35pm, Saturday, 10'th May 2025
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q1 2025 Results Conference Call May 8, 2025 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Rhonda Farnum - Chief Business Officer A
Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y
01:40pm, Friday, 09'th May 2025
TBPH reports weaker-than-expected first-quarter 2025 results. Collaboration revenues from Viatris rise year over year.
Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress
12:00pm, Friday, 09'th May 2025
DUBLIN , May 9, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced presentation of analyses of its previous Phase 3 program evalu
Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates
07:10pm, Thursday, 08'th May 2025
Theravance Biopharma (TBPH) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.09 per share a year ago.
Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update
04:05pm, Thursday, 08'th May 2025
YUPELRI® (revefenacin) net sales of $58.3 million, recognized by Viatris, increased 6% versus Q1 2024 1 TRELEGY net sales of $854M, as reported by GSK, increased 14% versus Q1 2024 2 CYPRESS study
Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress
06:00am, Monday, 28'th Apr 2025
DUBLIN , April 28, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that analyses of the initial Phase 3 program of ampreloxetin
Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
06:00am, Thursday, 24'th Apr 2025
DUBLIN , April 24, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2025 financial results and provide a business update after market close on Thursday, Ma
Analyses from Randomized Controlled Trials Further Support the Target Engagement and Safety Profile of Ampreloxetine in Neurodegenerative Disease DUBLIN , April 7, 2025 /PRNewswire/ -- Theravance Biop
Theravance Biopharma to Participate in an Upcoming Investor Conference
06:00am, Monday, 31'st Mar 2025
DUBLIN , March 31, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference in Las Vegas on Wedn
Why Is Theravance Bio (TBPH) Up 0.4% Since Last Earnings Report?
12:35pm, Friday, 28'th Mar 2025
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?
DUBLIN , March 27, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new analyses of the initial Phase 3 program of ampreloxetine
Theravance's Q4 Loss In Line With Estimates, Sales Beat
09:45am, Thursday, 27'th Feb 2025
TBPH's fourth-quarter earnings match estimates while sales beat the same marginally. Increased collaboration revenues from Viatris drive revenues higher.
Theravance Biopharma, Inc. (TBPH) Q4 2024 Earnings Call Transcript
08:58pm, Wednesday, 26'th Feb 2025
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q4 2024 Earnings Conference Call February 26, 2025 5:00 PM ET Company Participants Rick Winningham – Chief Executive Officer Rhonda Farnum – Chief Busines
Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates
06:16pm, Wednesday, 26'th Feb 2025
Theravance Biopharma (TBPH) came out with a quarterly loss of $0.05 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.03 per share a year ago.
Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results
04:05pm, Wednesday, 26'th Feb 2025
YUPELRI® (revefenacin) US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238.6 million in FY 2024, up 10% and 8%, respectively, compared with 2023 1 FY 20
